Figure 4.
![Figure 4. Survival analyses of intermediate cytogenetic risk AML patients with and without FLT3 ITD and/or NPM1 mutations. Kaplan-Meier estimates of OS (panels A and B) and EFS (panels C and D) for patients with intermediate-risk AML and FLT3 ITD mutations (FLT3 ITD positive [panels B and D]) versus those with intermediate-risk AML without FLT3 ITD mutations (FLT3 ITD negative [panels A and C]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/106/12/10.1182_blood-2005-05-2168/2/zh80240587560004.jpeg?Expires=1724895321&Signature=Z4gwLWkQ6KiaVbbZHOR8f~mJBrzQXCwArKSXXSh5BoC3CD9Lhgdf6xs-8nItrLuyOguFg6cI8UInhx6H7mMFweQxwuzoVqixM-rFrTlDU4O-pH7N5nXyXdtaHYYlKWgQaEXF-2V64dvo5wnEnw9sWvLvyE-jw9BiNKV7Zv8B-Oq89YXwxTv1V2agW~a65hc~GQUQjGEjBlCRRkBe60U0FKqs-MS6yERdrXXzoK6h1yoSllc36kjVwr13lx0EiEHNnvRN1ZO0YhcmTeI8cNkFMamJiJ7BNm6oEbYMKkWWtYGmM2Mz7bO33EQxw1BFQUC83sTlaF-EZNK1EwrpNvL~BQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Survival analyses of intermediate cytogenetic risk AML patients with and without FLT3 ITD and/or NPM1 mutations. Kaplan-Meier estimates of OS (panels A and B) and EFS (panels C and D) for patients with intermediate-risk AML and FLT3 ITD mutations (FLT3 ITD positive [panels B and D]) versus those with intermediate-risk AML without FLT3 ITD mutations (FLT3 ITD negative [panels A and C]).
